Published in J Clin Microbiol on April 01, 1994
Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure. J Bacteriol (1996) 3.32
Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting. J Clin Microbiol (1995) 2.88
Metabolism and genetics of Helicobacter pylori: the genome era. Microbiol Mol Biol Rev (1999) 1.92
Performance criteria of DNA fingerprinting methods for typing of Helicobacter pylori isolates: experimental results and meta-analysis. J Clin Microbiol (1999) 1.38
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.24
Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice. Antimicrob Agents Chemother (1999) 1.14
Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci (1997) 1.02
Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother (1995) 1.00
REP-PCR fragments as biomarkers for differentiating gastroduodenal disease-specific Helicobacter pylori strains. Dig Dis Sci (1998) 0.90
Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust (1985) 10.75
Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 9.49
Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol (1987) 7.09
Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. J Clin Microbiol (1986) 5.15
Restriction endonuclease analysis of the genome of Campylobacter pylori with a rapid extraction method: evidence for considerable genomic variation. J Infect Dis (1988) 3.96
Ribosomal RNA gene restriction patterns provide increased sensitivity for typing Salmonella typhi strains. J Infect Dis (1989) 3.76
Construction of a Helicobacter pylori genome map and demonstration of diversity at the genome level. J Bacteriol (1992) 3.16
Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile. J Clin Microbiol (1990) 2.53
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol (1988) 2.52
Ribotyping of Helicobacter pylori from clinical specimens. J Clin Microbiol (1992) 2.35
Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother (1992) 1.92
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust (1990) 1.44
Evidence of gastritis with several Helicobacter pylori strains. Lancet (1989) 1.43
Categorization of clinical isolates of Helicobacter pylori on the basis of restriction digest analyses of polymerase chain reaction-amplified ureC genes. J Clin Microbiol (1993) 1.36
Use of DNA restriction endonuclease digest and ribosomal RNA gene probe patterns to fingerprint Helicobacter pylori and Helicobacter mustelae isolated from human and animal hosts. Mol Cell Probes (1990) 1.24
Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol (1992) 1.16
Biotype and molecular fingerprints of metronidazole-resistant strains of Helicobacter pylori from antral gastric mucosa. J Med Microbiol (1993) 1.11
Ribosomal RNA gene patterns of Helicobacter pylori from surgical patients with healed and recurrent peptic ulcers. Epidemiol Infect (1992) 0.99
Use of plasmid profiles in the investigation of a patient with Helicobacter pylori infection and peptic ulcer disease. Am J Gastroenterol (1991) 0.87
Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet (1992) 4.54
Immune response to Campylobacter pyloridis in patients with peptic ulceration. Lancet (1985) 2.64
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology (1998) 2.62
Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides. J Bacteriol (1992) 1.98
Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother (1992) 1.92
Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol (1992) 1.76
Bacteremia caused by a recently described novel Desulfovibrio species. J Clin Microbiol (1997) 1.74
Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland. Antimicrob Agents Chemother (1991) 1.72
Low biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun (1992) 1.71
An acid extract as a common antigen in Campylobacter coli and Campylobacter jejuni strains. J Clin Microbiol (1983) 1.65
Serology of Campylobacter fetus ss. jejuni )"related" campylobacters). Demonstration of strain-specific and interstrain-related antigens by immunoelectrophoresis and co-agglutination. Acta Pathol Microbiol Scand B (1980) 1.64
Atypical campylobacters associated with gastroenteritis. J Clin Microbiol (1987) 1.62
Helicobacter pylori induces lymphocyte activation in peripheral blood cultures. Clin Exp Immunol (1990) 1.62
Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study. Scand J Gastroenterol (1991) 1.53
Isolation of group 2 aerotolerant Campylobacter species from Thai children with diarrhea. J Infect Dis (1991) 1.51
High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum (1994) 1.50
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology (1995) 1.49
Gastric cancer associated structure in mucus glycoproteins shown as a clinically useful marker. Gut (1991) 1.48
Intestinal metaplasia with colonic-type sulphomucins in the gastric mucosa; its association with gastric carcinoma. Acta Pathol Microbiol Scand A (1980) 1.47
Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose. J Bacteriol (1991) 1.46
Evidence that cagA(+) Helicobacter pylori strains are disappearing more rapidly than cagA(-) strains. Gut (2002) 1.43
Campylobacter enteritis in 188 hospitalized patients. Arch Intern Med (1983) 1.41
Prolonged campylobacter gastroenteritis in a patient with hypogammaglobulinaemia. Acta Med Scand (1983) 1.41
Serology of Campylobacter fetus ss. jejuni. 2 Serotyping of live bacteria by slide, latex and co-agglutination tests. Acta Pathol Microbiol Immunol Scand B (1982) 1.30
Reactive arthritis after campylobacter jejuni enteritis in patients with HLA-B27. Lancet (1980) 1.29
Arthritis associated with Campylobacter jejuni enteritis. Scand J Rheumatol (1981) 1.27
Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. Br J Clin Pharmacol (1976) 1.26
Review article: Pathogenesis of the transformation from gastritis to malignancy. Aliment Pharmacol Ther (1998) 1.23
Chemotaxis in yersinia arthritis. HLA-B27 positive neutrophils show high stimulated motility in vitro. Arthritis Rheum (1980) 1.21
Active treatment of chronic neck pain: a prospective randomized intervention. Spine (Phila Pa 1976) (2000) 1.18
Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol (1996) 1.18
Immunoblot confirmation of immune response to Campylobacter pyloridis in patients with duodenal ulcers. Med J Aust (1986) 1.18
Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease. J Clin Pathol (1996) 1.16
Campylobacter etiology in human gastroenteritis demonstrated by antibodies to acid extract antigen. J Clin Microbiol (1987) 1.16
Effect of erythromycin on the fecal excretion of Campylobacter fetus subspecies jejuni. J Infect Dis (1982) 1.16
Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol (1992) 1.16
Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer. Epidemiol Infect (2001) 1.16
Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol (1990) 1.14
Antibody response to Campylobacter pylori in diverse ethnic groups. Scand J Infect Dis (1988) 1.13
Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. Scand J Gastroenterol (2000) 1.13
Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut (1989) 1.12
Waterborne outbreak of Campylobacter enteritis after outdoors infantry drill in Utti, Finland. Epidemiol Infect (1989) 1.08
Depression of human neutrophil motility by influenza virus in vitro. Scand J Immunol (1977) 1.06
Heterogeneity of Campylobacter pylori as demonstrated by co-agglutination testing with rabbit antibodies. Scand J Gastroenterol Suppl (1988) 1.05
Colonoscopy in the diagnosis of antibiotic-associated colitis. A prospective study. Scand J Gastroenterol (1981) 1.05
Contact of lymphocytes with Helicobacter pylori augments natural killer cell activity and induces production of gamma interferon. Infect Immun (1993) 1.05
Campylobacter upsaliensis-associated diarrhea in human immunodeficiency virus-infected patients. Clin Infect Dis (1998) 1.05
Chronic diarrhea due to a single strain of Aeromonas caviae. Eur J Clin Microbiol Infect Dis (1995) 1.04
Antibody response to Campylobacter pylori in an ethnic group lacking peptic ulceration. Scand J Infect Dis (1988) 1.03
High frequency of helicobacter negative gastritis in patients with Crohn's disease. Gut (1996) 1.03
Effect of ABO blood group and secretor status on the frequency of Helicobacter pylori antibodies. Scand J Gastroenterol (1990) 1.03
Biochemical characterization of Campylobacter fetus lipopolysaccharides. Infect Immun (1994) 1.02
Clinical and serological studies in patients with Campylobacter fetus ssp. jejuni infection: II. Serological findings. Infection (1981) 1.02
Antibodies against an acid extract from a single campylobacter strain in hospitalized campylobacter patients. Infection (1983) 1.01
Carditis and arthritis associated with Campylobacter jejuni infection. Acta Med Scand (1980) 1.01
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther (2002) 1.01
Defective chemotaxis in monosomy-7. Nature (1977) 0.99
Allergy gap between Finnish and Russian Karelia on increase. Allergy (2011) 0.99
Gastroenteritis associated with Campylobacter cinaedi. Med J Aust (1989) 0.98
The relationships between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther (1996) 0.98
Infection with Campylobacter fetus. Scand J Infect Dis (1984) 0.96
Detection of an organ specific protein in the rat thymus. Ann Med Exp Biol Fenn (1966) 0.96
Use of leucocyte migration under agarose to study spontaneous and directed locomotion of leucocytes. Immunology (1978) 0.96
Helicobacter pylori and associated gastroduodenal diseases. Review article. APMIS (1991) 0.96
Chronic antral gastritis, Lewis(a+) phenotype, and male sex as factors in predicting coexisting duodenal ulcer. Scand J Gastroenterol (1989) 0.95
Analysis of Campylobacter jejuni antigens with monoclonal antibodies. J Clin Microbiol (1984) 0.95
Function of neutrophils in preleukaemia. Scand J Haematol (1977) 0.95
Lymphocyte activation in vivo in the intestinal mucosa of patients with Crohn's disease. J Clin Lab Immunol (1987) 0.93
Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. Gut (1994) 0.93
Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. Hepatology (1995) 0.92
Serological analysis of the heat-stable antigens involved in serotyping Campylobacter jejuni and Campylobacter coli. APMIS (1989) 0.92
A member of the delta subgroup of proteobacteria from a pyogenic liver abscess is a typical sulfate reducer of the genus Desulfovibrio. J Clin Microbiol (2001) 0.91
Cystic 'hamartomatous' gastric polyps: a disorder of oxyntic glands. Histopathology (1983) 0.91
Genetic and environmental factors in the immunopathogenesis of atopy: interaction of Helicobacter pylori infection and IL4 genetics. Int Arch Allergy Immunol (2005) 0.91
Development of an immunoassay for rapid detection of ganglioside GM(1) mimicry in Campylobacter jejuni strains. J Clin Microbiol (2001) 0.90
Bactericidal effect of bovine normal and immune serum, colostrum and milk against Helicobacter pylori. J Appl Bacteriol (1995) 0.90
Waterborne Campylobacter jejuni epidemic in a Finnish hospital for rheumatic diseases. Scand J Infect Dis (1990) 0.90
Infection due to Campylobacter jejuni: a report of 524 outpatients. Infection (1984) 0.90
Budesonide enema in active haemorrhagic proctitis--a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther (1994) 0.89
Phagocytic activity of neutrophilic leukocytes of A2 influenza patients. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 0.89
Chronic nonatropic ('superficial') gastritis increases the risk of gastric carcinoma. A case-control study. Scand J Gastroenterol (1994) 0.89
Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol (1987) 0.89
Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori. J Antimicrob Chemother (1998) 0.88
Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. Br J Pharmacol (2013) 0.88
Hunt for the origin of allergy - comparing the Finnish and Russian Karelia. Clin Exp Allergy (2015) 0.88
In vitro effect of anti-inflammatory agents on phagocytosis and bacterial killing by human neutrophilic leukocytes. Acta Pharmacol Toxicol (Copenh) (1972) 0.87
Change in the pattern of IgE reactivity to timothy grass and birch pollen allergens over a 20-year period. J Investig Allergol Clin Immunol (2006) 0.86
Leukocyte migration agarose test for the assessment of human neutrophil chemotaxis. II. Variables in the attraction assay. Scand J Immunol (1977) 0.86
Comparison of a blood-free medium and a filtration technique for the isolation of Campylobacter spp. from diarrhoeal stools of hospitalised patients in central Australia. J Med Microbiol (1992) 0.86
In vitro activity of antifungal azoles against Helicobacter pylori. Eur J Clin Microbiol Infect Dis (1992) 0.86
Evaluation of the E test in testing susceptibility of Pseudomonas aeruginosa to tobramycin. Eur J Clin Microbiol Infect Dis (1992) 0.86
Campylobacter jejuni/Campylobacter coli-associated Guillain-Barré syndrome. Immunoblot confirmation of the serological response. Med J Aust (1987) 0.85
Rate of Helicobacter pylori acquisition among Finnish adults: a fifteen year follow-up. Scand J Gastroenterol (1996) 0.85